9701 Richmond Avenue
About RadioMedixRadiomedix,Inc. is a privately held biotechnology company founded in 2006 to develop and commercialize technology and products which will enable on-site and on-demand access to Positron Emission Tomography (“PET”). RadioMedix is developing its own chelation technology and new imaging conjugates, GlucoMedix and OncoMedix, which have the potential to significantly improve diagnosis and treatment monitoring for a variety of cancers.
CEO: Ebrahim S Delpassand
CSO: Izabela Tworowska
Tweets by RadioMedix
14 articles with RadioMedix
Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme
Vect-Horus and RadioMedix are pleased to announce the FDA clearance of exploratory Investigational New Drug (eIND) application to evaluate 68 Ga-RMX-VH for the detection and mapping of Low Density Lipoprotein Receptor (LDLR) overexpressed in Glioblastoma Multiforme (GBM).
RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit
RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for the 2020 TechConnect Innovation Award.
Radiomedix a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer, announced the appointment of Dr. Ferey Faridian as a member of its Board of Directors.
ITM and RadioMedix announce Drug Master File Submission for ITM’s 68Ge/68Ga Generator GeGant® for the U.S. Market
ITM Isotopen Technologien München AG and RadioMedix Inc. announced that ITM has filed a Drug Master File with the U.S. Food and Drug Administration for ITM’s next generation Germanium-68/Gallium-68 Generator, which is manufactured at the RadioMedix Spica Center in Houston, Texas, U.S. and distributed under the brand name GeGant®.
RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program by the National Institute of Health SBIR/STTR program office.
Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology.
Vect-Horus and RadioMedix Announce Signing of a Letter of Intent to Co-Develop a Radio-Theranostic Agent for Glioblastoma
This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and clinical trials with radiopharmaceuticals.
RadioMedix Inc. and ITM Isotopen Technologien München (ITM) announced today that ITM’s subsidiary, Isotope Technologies Garching GmbH (ITG), and RadioMedix have signed a manufacturing and supply agreement for the production of the next generation of Ge-68/Ga-68
Radiomedix and AREVA Med Announce Initiation of Phase I Clinical Trial of Alphamedix, a Targeted Alpha Therapy for Patients With Neuroendocrine Tumors
Patients will be enrolled at Excel Diagnostic and Nuclear Oncology Center (Houston, TX).
RadioMedix Selected for National Cancer Institute's Investor Initiatives and Presentation at BIO Investor Forum
t is a unique opportunity to present pipeline of RadioMedix products and offer clinical and R&D services to biopharma experts and investors.
Extended Partnership Between RadioMedix And ITM´s Subsidiary ITG For Exclusive Distribution Of N.C.A Lutetium-177 In North America
RadioMedix Release: First U.S. Multi-Center Investigational Clinical Trial Of 177 Lu PSMA-617 Targeted Radioligand Therapy In Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
RadioMedix And AREVA Med – SBIR NCI Contract Grant Awarded To Develop Targeted Alpha-Emitter Therapy Of Neuroendocrine Tumors With Lead-212
RadioMedix Successfully Completed The Phase I/ II Clinical Studies For Aminomedix Used For Radiation Kidney Protection During Peptide-Receptor Radionuclide Therapy (PRRT)